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اُت الُكَريَّاِت البيِض الَبَشرِيَّة يف مرض املرحلة االخرية  العالقة بني انواع ُمْسَتِضدَّ
من الفشل الكلوي املصاحب الرتفاع ضغط الدم بني املرضى اليمنيني
جماهد يحى ن�سار، ح�سن عبدالوهاب ال�سماحي، هيثم م�سعود
abstract: Objectives: Many studies have attempted to locate a connection between various genetic factors and 
the pathogenesis of certain diseases. A number of these have found human leukocyte antigens (HLAs) to be the 
most significant genetic factors affecting the susceptibility of an individual to a certain disease. The present case-
control study aimed to determine the connection between class I and class II HLAs and cases of hypertensive 
end-stage renal failure (HESRF), as contrasted with healthy controls, in Yemen. Methods: The study was carried 
out between March 2013 and March 2014 and included 50 HESRF patients attending the Urology & Nephrology 
Center at Al-Thawra University Hospital in Sana’a, Yemen, and 50 healthy controls visiting the same centre for 
kidney donation. Among both patients and controls, HLA class I (A, B and C) and class II (DRB1) genotypes were 
determined by polymerase chain reactions. Results: There was an association (odds ratio: 4.0) with HLA-A9(24) 
and HESRF, although this was not statistically significant. A significant protective function was found for the HLA-
CW3 and DRB1-8 genes against the development of HESRF. Although HLA-B14 was present in some patients (0.06) 
and not in the controls, this difference was not statistically significant enough to conclude that HLA-B14 plays a 
role in the genetic predisposition for end-stage renal disease development. There was a high frequency of HLA-A2, 
B5, CW6, DRB1-3, DRB1-4 and DRB1-13 in both patients and controls. Conclusion: Although no HLAs were 
found to play a highly significant role in genetic predisposition to HESRF, certain HLA genes could be considered 
as protective genes against HESRF development.  
Keywords: Hypertension; Renal Failure, End-Stage; HLA Antigens; Case-Control Study; Yemen.
امللخ�ص: الهدف: حاولْت العديد ِمْن الِدرا�ساِت حَتديد العالقة بني العوامِل الوراثيِة امُلْخَتِلفِة وحدوث َبْع�ض االأمرا�ِض. َوجد عدد ِمْن هذه 
هّدفْت  االمرا�ض.  ببع�ض  لال�سابة  اأكرب  ب�سورة  االفراد  بع�ض  وتعر�ض  ة  يَّ الَب�رَشِ البي�ِض  اِت  الُكَريَّ اُت  دَّ ُم�ْسَت�سِ انواع  الدرا�ساَت عالقة بني 
ة وحدوث الف�سل الكلوي امل�ساحب ارتفاع  يَّ اِت البي�ِض الَب�رَشِ اُت الُكَريَّ دَّ الدرا�سُة لَتْقرير العالقِة بني ال�سنِف االول وال�سنِف الّثاين من ُم�ْسَت�سِ
اُت بني اال�سحاء كعينة للمقارنة. الطريقة: ُنّفذْت الدرا�سة بني مار�ض2013  دَّ �سغط الدم بني املر�سى و مقارنة ذلك بانت�سار هذه امُل�ْسَت�سِ
واآذاِر 2014 وَت�سّمنْت 50 من مر�سى الف�سل الكلوي امل�ساحب الرتفاع �سغط الدم الذين و�سلوا اىل مركَز طّب الِكلى وطّب املجاري البوليَة 
يف م�ست�سفى الثورِة اجلامعي يف �سنعاء، اليمن، و 50 من اال�سحاء الذين راجعو نف�ض املركِز للترّبِع بالكلِى. مت ت�سنيف جينات ال�سنِف 
املت�سل�سلِة.  ُبوليمرِياز  تفاعالت  بطريقة  واال�سحاء  املر�سى  ة بني كال من  يَّ الَب�رَشِ البي�ِض  اِت  الُكَريَّ اُت  دَّ ُم�ْسَت�سِ من  الّثاين  وال�سنِف  االول 
الَنتائِج: كان هناك عالقة )َلي�َست ذو داللة اإح�سائيةُ( بن�سبة اإحتماالِت: 4.0 بني )HLA-A9)24 و HESRF، كما وجدت و ظيفة و قائية 
)0.06( ومَل يكن موجَد يف  جني َكاَن موجود يف َبْع�ض املر�سى   HLA-B14 اأن  DRB1-8. وبالرغم من  و   HLA-CW3 هاّمة جلينات 
اال�سحاء اال ان هذا االإختالِف ملا يَكَن هامَّ ب�سكل اإح�سائي مبا فيه الكفاية الإ�ْسِتْنتاج امليِل الوراثِي لتطويِر املر�ِض الكلوِي النهائِي ب�سبب 
وجود هذا اجلني. كان هناك تكرار اإت�ض اإل اأي اأي-HLA-A2( 2(، اإت�ض اإل اأي بي )HLA-B5(، اإت�ض اإل اأي �سي دبليو )HLA-CW6( واإت�ض 
اإل اأي دي اآر بي )HLA-DRB1-3, HLA-DRB1-4 و HLA-DRB1-13( يف كال من املر�سى و عينة املقارنة من اال�سحاء. اخلامتة: 
ة اال اننا  يَّ اِت البي�ِض الَب�رَشِ اُت الُكَريَّ دَّ بالرغم من اأن الِدرا�سة مل تثبت وجود عالقة ذات اهمية بني ن�سوء الف�سل الكلوي وبع�ض انواع ُم�ْسَت�سِ
ِكُن اأَْن ُتعَترَب اأن بع�ض اجلينات من اللمكن ان تكون لها وظيفة وقائية �سّد ن�سوء الف�سل الكلوي امل�ساحب الرتفاع �سغط الدم. مُيْ
ة؛ درا�سة مقارنة؛ اليمن. يَّ اِت البي�ِض الَب�رَشِ اُت الُكَريَّ دَّ مفتاح الكلمات: اإرتفاع �سغط الدم؛ الف�سل الكلوي، مرحلة نهائيِة؛ ُم�ْسَت�سِ
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Advances in Knowledge 
- This study gives information about human leukocyte antigens (HLA) in individuals from Yemen and investigates the relationship 
between HLAs and hypertensive end-stage renal failure (HESRF). 
- This study provides important information as it is the first time that the frequency of HLA genes in the general Yemeni population and 
in HESRF Yemeni patients has been investigated.
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The progression of chronic renal failure (CRF) usually leads to end-stage renal disease (ESRD), at which point renal 
replacement therapy is the only option. Since the 
mid-1980s, there has been a noticeable rise in the 
incidence and prevalence of ESRD around the world.1–4 
Gender, genetic profile, ethnicity, lipids, hypertension 
and smoking have been identified as factors which 
can influence the development of ESRD.4,5 However, 
there is a need for further research to be carried out 
on the role of the immune system in renal diseases, 
as this could be the origin or cause of the disease 
and its progression.6 This theory is the outcome of 
investigations into positive relations between human 
leukocyte antigens (HLAs) and a broad variety of renal 
diseases.6 Studies have illustrated some significant 
associations between HLA class I and II alleles with 
renal diseases. Methods for associating HLAs with 
renal disease have been developed since the late 1980s, 
mostly as a result of more detailed knowledge of class 
I and II molecules and their structure and function. 
HLA phenotypes are interrelated, with an increased 
or reduced risk of alloantibody sensitisation in ESRD 
candidates for first or repeat kidney transplantation.6 
The incidence and prevalence of ESRD and 
its relationship with class I and II HLA alleles in 
patients from Yemen and other Middle Eastern and 
Arab countries has only recently been studied due 
to deficiencies in national epidemiological research. 
Prior to this study, no information was available on the 
frequency of class I and II HLAs, either in the Yemeni 
population in general or in hypertensive end-stage 
renal failure (HESRF) patients. As such, this case-
control study aimed first to determine the relationship 
between HLA class I (A, B and C) and class II (DRB1) 
with HESRF. Second, it aimed to compare the HLAs 
found to have a relationship with HESRF with those 
from other races or national groups outside of Yemen 
in a literature review. Third, this study was designed 
to determine the potential genes that might give 
protection from HESRF development.
Methods 
This case-control study was carried out over a 12-month 
period between March 2013 and March 2014. A total of 
100 individuals were enrolled in the study; the patient 
group comprised 50 adults with HESRF while the 
control group consisted of 50 healthy adult individuals. 
All patients and controls originated from Sana’a, 
Yemen. The patient group consisted of 40 males and 10 
females (aged from 18 to 57 years) who had attended 
the Urology & Nephrology Center at Al-Thawra 
University Hospital in Sana’a for a kidney transplant. 
Hypertension was the cause of renal failure in all of 
these patients. All of the patients showed proteinuria 
and underwent a kidney biopsy to exclude an extensive 
focal and global glomerulosclerosis association 
with the APOL1 gene. All HESRF patients in the 
study were on haemodialysis before they underwent 
kidney transplantation. 
The control group consisted of 32 males and 18 
females (aged from 18 to 57 years) who had visited the 
Urology & Nephrology Center at Al-Thawra University 
Hospital for a kidney donation. They were confirmed 
to be healthy following a clinical examination by 
specialist physicians. As age and gender does not 
influence an individual’s HLA frequency profile, the 
control group was not age- and gender-matched with 
the patient group. Both the patients and controls 
were required to undergo certain tests, including 
blood pressure, abdominal ultrasound, complete 
blood count, blood sugar, kidney and liver function 
tests. In addition, a general urine examination and a 
24-hour urine examination for protein detection and 
creatinine clearance were carried out. Results for 
all of the aforementioned tests were normal in the 
control group. 
 HLA genotyping was completed for each individual 
in the patient and control groups. Blood specimens were 
collected and treated with ethylenediaminetetraacetic 
acid. As the time of blood collection has no effect on 
genotyping results, blood specimens were collected 
whenever patients arrived at the hospital. Blood 
specimens from both groups were used for HLA class I 
(A, B and C) and class II (DRB1) genotyping.
The typing of all of the subjects’ HLA-A, -B, -C 
and -DRB1 alleles were identified using low-resolution 
BAGene Sequence Specific Primers polymerase 
chain reaction kits (BAG Health Care GmbH, Lich, 
Germany). The tests were carried out according to the 
manufacturer’s instructions. The genomic DNA of each 
- The findings revealed an association between HLA-A9(24) and HESRF and a highly significant protective function for the HLA-CW3 
and DRB1-8 genes against HESRF development. 
Application to Patient Care
- Research in the HLA field is still in its early stages in Yemen. It is therefore necessary to study the relationship between HLAs and various 
diseases in Yemen in order to improve treatment options for affected patients.
- The incidence and social burden of end-stage renal disease is growing. Slowing or preventing the progression of this disease to renal 
failure is an important public health priority.
Mogahid Y. Nassar,Hassan A. Al-Shamahy and Haitham A. A. Masood
Clinical and Basic Research | e243
sample was purified using the spin columns method of 
the QIAGEN DNA purification kit (QIAGEN, Hilden, 
Germany). Allele frequencies in HESRF patients and 
controls were calculated by direct counting.7 
The association of HESRF with HLA-I alleles was 
analysed by comparing the frequency of HLA-A and 
-B alleles in the HESRF patients with those in the 50 
healthy controls. The maximum likelihood method 
was used to evaluate the haplotype frequencies for the 
two loci of HLA. The Chi-squared test for two-way 
tables after Yates correction for continuity was used 
to define the differences between allele frequencies in 
patients and controls, using the Epi Info™ programme, 
Version 6 (Centers for Disease Control and Prevention, 
Atlanta, USA). The odds ratios (OR) with 95% 
confidence intervals (CI) were calculated. A P value of 
<0.05 was considered significant.
The study was approved by the Department of 
Medical Microbiology & Clinical Immunology in 
the Faculty of Medicine & Health Sciences at Sana'a 
University, Yemen. Written consent was obtained 
from all of the participants in the study.
Results
The age and gender of the subjects in the patient and 
control groups are shown in Table 1. The HESRF 
patients’ mean age was 38.03 ± 10.9 years and that 
of the controls was 35.15 ± 8.9 years (range: 18–57 
years for both groups). A total of 40 patients (80%) 
were male and the remaining 10 patients (20%) were 
female. There were 32 male (64%) and 18 female (36%) 
controls [Table 1].
The results showed that HLA-A2 and A9 had the 
highest frequency among HLA-A alleles in the patients 
(0.48 and 0.18); HLA-A2 and A3 were most frequent 
among the controls (0.48 and 0.16). HLA-A28 and A1 
were the next most frequent alleles in the patient group, 
whereas HLA-A28 and A9 were the next most frequent 
alleles in the controls. A comparison of the frequency 
of HLA-A alleles in the patients and controls showed 
higher frequencies of HLA-A9(24) (OR = 4.0, 95% 
CI = 0.42–103.9; P = 0.16) and A9 (OR = 1.98; 
P = 0.24) and lower frequencies of HLA-A19(30) 
(OR = 0.0; P = 0.04) and A19(33) (OR = 0.23; 
P = 0.16) in the HESRF patients [Table 2].
The most numerous HLA-B allele in the patients 
was HLA-B5. This allele was articulated in the HESRF 
patients at a higher frequency in comparison to the 
controls (0.26 versus 0.18; OR = 1.65; P = 0.33). On the 
other hand, the HLA-B16(38), 21(49), 70 and 73 alleles 
were among the least expressed HLA-B alleles in the 
patients. A total of 10 alleles were not found at all in the 
control group (B14, 21[44], 21[45], 27, 40, 40[60], 50, 
51, 53, 62 and 78). The most frequent alleles expressed 
in the control subjects was HLA-B5 (OR = 1.65; 
P = 0.33) and B35 (OR = 0.46; P = 0.21). HLA-B21 
and 21(50) were also observed at a lower frequency in 
the patients compared to the controls (OR = 0.47; 
P = 0.29 each) [Table 3].
The results showed that HLA-CW6 and CW7 had 
the highest frequency among HLA-CW alleles in the 
patients (0.44 and 0.38, respectively) and the controls 
(0.52 and 0.38, respectively). HLA-CW4 and CW2 
were the next most frequent alleles in the patients 
(0.28 and 0.12, respectively); HLA-CW4 and CW3 
were next most frequent in the controls (0.26 and 0.14, 
respectively). In comparison, the HLA-CW3 allele was 
not found among the patients (P = 0.006), indicating a 
probable protective function [Table 4]. 
The results showed that DRB1-4 and 13 had 
the highest frequency among DRB1 alleles in the 
patients (0.32 and 0.34, respectively) and controls 
(0.42 and 0.30, respectively). DRB1-3 was the next 
most frequent allele in the patients and controls (0.26 
each). A comparison of the frequency of DRB1 alleles 
among those in the patient and control groups showed 
higher frequencies of DRB1-8 in the controls (0.12), 
while in the patients it was 0.02 (OR = 0.15; P = 0.05), 
indicating a probable protective function. In addition, 
a comparison of the frequency of DRB1 alleles between 
both groups showed higher frequencies of DRB1-10 
(OR = 2.3, 95% CI = 0.71–7.8; P = 0.11) and 15 (OR = 2.3, 
95% CI = 0.63–8.4; P = 0.16) and lower frequencies of 8 
(OR = 0.15; P = 0.05) in the HESRF patients [Table 5]. 
Discussion
Renal failure is mainly caused by a patient suffering 
from chronic high blood pressure over a period of 
Table 1: Age and gender of Yemeni hypertensive-end 






n % n % n %
Age in years
18–27 35 70 31 62 66 66
28–37 8 16 12 24 20 20
38–47 5 10 6 12 11 11
48–57 2 4 1 2 3 3
Gender
Male 40 80 32 64 72 72
Female 10 20 18 36 28 28
Total 50 100 50 100 100 100
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many years. Hypertension is also the second main 
cause, after diabetes, of ESRD and is accountable 
for 25–30% of all reported cases.8 Hypertension 
is an important risk factor for the progression of 
ESRD in women as well as men.9 Certain ethnicities, 
such as those of black African origin, have a high 
prevalence of the more severe form of hypertension; 
in addition, these patients have a higher prevalence of 
hypertension occurring at an earlier age than patients 
of white Caucasian origin.10 Essentially, hypertension 
suggests that at least one of the genes to blame for the 
genetic susceptibility to ESRD is to be found in or close 
to the HLA complex.11,12
Many studies have been performed worldwide on 
the HLA complex and disease, including in various 
Arab countries, but this type of research is still in its 
infancy in Yemen. Indeed, to the best of the authors’ 
knowledge, the current study was the first in Yemen on 
HLA typing. The annual incidence of ESRD in Yemen 
is 120 per million which is comparable to the incidence 
reported in other countries of the same region.13 This 
study aimed mainly to investigate the association 
Table 2: Human leukocyte antigen-A (HLA-A) and gene frequency in Yemeni hypertensive-end stage renal disease 
patients and healthy controls (N = 100)











1 7 0.14 0.072 4 0.08 0.040 1.9 (0.5–8.3 0.33
2 24 0.48 0.279 24 0.48 0.279 1 (0.4–2.4) 0.84
3 3 0.06 0.030 8 0.16 0.083 0.34 (0.1–1.5) 0.11
9 9 0.18 0.094 5 0.10 0.051 1.98 (0.54–7.5) 0.24
9(23) 5 0.10 0.051 3 0.06 0.030 1.74 (0.3–9.8) 0.48
9(24) 4 0.08 0.040 1 0.02 0.010 4.0 (0.42–103.9) 0.16
10 1 0.02 0.010 4 0.08 0.040 0.23 (0.01–2.3) 0.18
10(25) 1 0.02 0.010 0 0.00 0.000 Undefined 0.3
10(26) 1 0.02 0.010 0 0.00 0.000 Undefined 0.3
11 2 0.04 0.020 3 0.06 0.030 0.65 (0.1–5.1) 0.6
19 3 0.06 0.015 5 0.10 0.051 0.6 (0.1–2.99) 0.46
19(24) 1 0.02 0.010 0 0.00 0.000 Undefined 0.31
19(29) 1 0.02 0.010 1 0.02 0.010 1 (0.0–37.8) 0.84
19(30) 0 0.00 0.000 4 0.08 0.040 0.0 (0.0–1.5) 0.04
19(31) 0 0.00 0.000 2 0.04 0.020 0.0 (0.0–4.1) 0.15
19(32) 3 0.06 0.030 2 0.04 0.020 1.5 (0.2–13.8) 0.64
19(33) 1 0.02 0.010 4 0.08 0.040 0.23 (0.01–2.37) 0.16
23 0 0.00 0.000 2 0.04 0.020 0.0 (0.0–4.1) 0.15
24 0 0.00 0.000 2 0.04 0.020 0.0 (0.0–4.1) 0.15
28 8 0.16 0.083 6 0.12 0.062 1.4 (0.4–5.03) 0.56
29 2 0.04 0.020 0 0.00 0.000 Undefined 0.15
30 2 0.04 0.020 4 0.08 0.04 0.48 (0.06–3.2) 0.4
31 1 0.02 0.010 0 0.00 0.000 Undefined 0.31
32 2 0.04 0.020 1 0.02 0.010 2.04 (0.14–58.9) 0.55
33 3 0.06 0.030 5 0.10 0.051 0.6 (0.1–2.99) 0.46
36 0 0.00 0.000 1 0.02 0.010 0.0 (0.0–17.6) 0.31
80 0 0.00 0.000 1 0.02 0.010 0.0 (0.0–17.8) 0.31
*P <0.05 was considered statistically significant.
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Table 3: Human leukocyte antigen-B (HLA-B) and gene frequency in Yemeni hypertensive end-stage renal disease 
patients and healthy controls (N = 100)













5 13 0.26 0.139 9 0.18 0.094 1.65 (0.6–4.6) 0.33
5(51) 4 0.08 0.040 4 0.08 0.040 1.0 (0.2–5.1) 0.84
5(52) 2 0.04 0.020 1 0.02 0.010 2 (0.14–5.8) 0.55
7 3 0.06 0.030 5 0.10 0.051 0.6 (0.1–2.99) 0.46
8 4 0.08 0.040 3 0.06 0.030 1.4 (0.24–8.2) 0.7
12 1 0.02 0.010 2 0.04 0.020 0.49 (0.02–7.23) 0.55
12(44) 7 0.14 0.073 5 0.10 0.051 1.47 (0.38–5.8) 0.53
13 2 0.04 0.020 1 0.02 0.010 2.04 (0.14–5.8) 0.55
14 3 0.06 0.030 0 0.00 0.000 Undefined 0.07
16 1 0.02 0.010 3 0.06 0.030 0.32 (0.01–3.6) 0.3
16(38) 0 0.00 0.000 1 0.02 0.010 0 (0.0–17.5) 0.31
16(39) 1 0.02 0.010 2 0.04 0.020 0.49 (0.02–7.2) 0.55
17 6 0.12 0.062 6 0.12 0.062 1 (0.26–3.1) 0.84
17(57) 2 0.04 0.020 5 0.10 0.051 0.38 (0.05–2.3) 0.23
17(58) 1 0.02 0.010 1 0.02 0.012 1 (0.0–37.8) 0.84
18 5 0.10 0.051 3 0.06 0.030 1.7 (0.3–9.8) 0.46
21 3 0.06 0.030 6 0.10 0.060 0.47 (0.1–2.3) 0.29
21(44) 1 0.02 0.010 0 0.00 0.000 Undefined 0.31
21(45) 1 0.02 0.010 0 0.00 0.000 Undefined 0.31
21(49) 0 00.00 0.000 2 0.04 0.020 0.0 (0.0–4.1) 0.15
21(50) 3 0.06 0.030 6 0.12 0.062 0.47 (0.09–2.3) 0.29
22 1 0.02 0.010 1 0.02 0.010 1 (0.0–37) 0.84
27 1 0.02 0.010 0 0.00 0.000 Undefined 0.31
35 4 0.08 0.041 8 0.16 0.083 0.46 (0.11–1.8) 0.21
37 2 0.04 0.020 2 0.04 0.020 1 (0.1–10.5) 0.84
40 1 0.02 0.010 0 0.00 0.000 Undefined 0.31
40(60) 1 0.02 0.010 0 0.00 0.000 Undefined 0.31
41 4 0.08 0.041 4 0.08 0.041 1 (0.19–5.14) 0.84
50 1 0.02 0.010 0 0.00 0.000 Undefined 0.31
51 2 0.04 0.020 0 0.00 0.000 Undefined 0.15
52 1 0.02 0.010 0 0.00 0.000 Undefined 0.31
53 6 0.12 0.062 4 0.08 0.041 1.6 (0.4–7.2) 0.5
62 1 0.02 0.010 0 0.00 0.000 Undefined 0.31
70 0 0.00 0.000 1 0.02 0.010 0.0 (0.0–17.5) 0.31
72 1 0.02 0.010 2 0.04 0.020 0.49 (0.02–7.2) 0.55
73 0 0.00 0.000 1 0.02 0.010 0.0 (0.0–17.5) 0.31
78 2 0.04 0.020 0 0.00 0.000 Undefined 0.15
 
*P <0.05 was considered statistically significant.
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between HLAs (A, B, CW and DRB1) and HESRF in 
comparison with healthy individuals. 
In this study, the male-to-female patient ratio was 
4:1. The high prevalence of renal disease among males 
might be due to physiological differences between the 
genders as well as the higher susceptibility of males 
to hypertension, which can lead to renal failure. The 
higher prevalence of hypertension among males in 
this study was in agreement with the findings of 
another study, which reported a male-to-female ratio 
of 2:1.14 The present study also concurred with that of 
Hsu et al., who reported that the male gender was a 
risk factor for ESRD.15 Another possible reason could 
be the statistically small sample size of females in 
the current study, partly due to the fact that Yemeni 
females have less access than males to medical services 
due to social and cultural reasons.16 
The findings of this study revealed the phenotypic 
and gene frequencies of the HLA-A, HLA-B, HLA-CW 
and HLA-DRB1 genes in 100 Yemenis (50 patients and 
50 controls). HLA-B14 was found in three patients, 
but was not identified in the controls. The patients, 
as compared to the controls, had lower frequencies 
of certain HLA genes such as HLA-A19(30), CW3 
and DRB1-8. These genes were found in the controls 
but not in the patients, apart from DRB1-8 which was 
found in one patient.
On the other hand, there was no statistically 
significant difference between the renal failure 
Table 4: Human leukocyte antigen-CW (HLA-CW) and gene frequency in Yemeni hypertensive end-stage renal 
disease patients and healthy controls (N = 100)













1 1 0.02 0.010 1 0.02 0.010 1 (0.0–3.7) 0.84
2 6 0.12 0.062 6 0.12 0.062 1 (0.26–3.9) 0.84
3 0 0.00 0.000 7 0.14 0.072 0 (0.0–0.72) 0.006
4 14 0.28 0.151 13 0.26 0.139 1.1 (0.42–2.9) 0.82
5 1 0.02 0.010 3 0.06 0.030 0.3 (0.01–3.6) 0.30
6 22 0.44 0.252 26 0.52 0.307 0.73 (0.3–1.7) 0.42
7 19 0.38 0.213 19 0.38 0.213 1 (0.41–2.4) 0.84
*P <0.05 was considered statistically significant.
Table 5: Human leukocyte antigen-DRB1 (HLA-DRB1) and gene frequency in Yemeni hypertensive end-stage renal 
disease patients and healthy controls (N = 100)
HLA-
DRB1












1 7 0.14 0.072 9 0.18 0.094 0.74 (0.22–2.4) 0.58
3 13 0.26 0.139 13 0.26 0.139 1 (0.37–2.7) 0.84
4 16 0.32 0.175 21 0.42 0.238 0.65 (0.26–1.6) 0.3
7 7 0.14 0.073 9 0.18 0.094 0.74 (0.22–2.4) 0.58
8 1 0.02 0.010 6 0.12 0.060 0.15 (0.01–1.3) 0.05
10 12 0.24 0.128 6 0.12 0.060 2.3 (0.71–7.8) 0.11
11 5 0.10 0.051 3 0.06 0.030 1.74 (0.33–9.9) 0.46
12 0 0.00 0.000 1 0.02 0.010 0.0 (0.0–176) 0.31
13 17 0.34 0.188 15 0.30 0.163 1.2 (0.48–3.0) 0.66
14 3 0.06 0.030 1 0.02 0.010 3.13 (0.3–80.9) 0.30
15 10 0.20 0.106 5 0.10 0.051 2.3 (0.63–8.4) 0.16
16 4 0.08 0.040 5 0.10 0.051 0.78 (0.16–3.7) 0.72
*P <0.05 was considered statistically significant.
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patients and the controls; this suggests that there 
are no HLA genes predisposing to ESRD. This result 
was in agreement with those of Agrawal et al. and 
Prasanavar et al. who determined that HLA and 
haplotype frequencies were not significantly different 
in renal transplant patients and healthy donors.17,18 
This contrasts sharply with another study that 
compared race-matched controls of white Caucasian 
and black African ethnicity and showed how genetic 
differences associated with the HLA system accounted 
for racial differences in hypertensive renal failure.19 A 
comparison between patients of white Caucasian and 
black African ethnicity with hypertensive renal failure 
demonstrated that the patients of black African origin 
had an increased frequency of HLA-DR3 alleles, which 
was greater than that normally known to exist among 
healthy individuals.19 
These outcomes differ from the results of the 
current study which found no statistically significant 
differences between the patients and controls. 
However, this might be due to the fact that patients 
and healthy controls in this study were genetically 
similar; in fact, some of the patients and controls 
were related by family. However, the authors of the 
current study were of the opinion that it can be helpful 
to compare relatives; if there is a higher frequency of 
similar genes it is easier to indicate susceptibility to the 
disease rather than to race. It may also be the case that 
patients and controls were subjected to similar racial, 
genetic and environmental factors that may contribute 
to the development of ESRD.
Zachary et al. also found that frequencies of HLA 
alleles and their distribution among donors and renal 
patients in the United Network for Organ Sharing 
(UNOS) registry varied between races.20 However, no 
difference was found in disease susceptibility; this was 
in agreement with the current study. Similarly, several 
studies have indicated racial differences in HLAs and 
their relationships with many diseases.4 The results of 
the current study were similar to those of Crispim et 
al. who described associations of class I and II HLAs 
with ESRD, independent of other factors, among CRF 
patients with a variety of diagnoses.21 Crispim et al. 
found that the antigens positively associated with 
ESRD were HLA-A78 and HLA-DR11.21
In a previous study among Mapuche and non-
Mapuche people in Chile, HLA-B8 alleles were found 
significantly more frequently in Mapuche recipients 
than in non-Mapuche recipients and Mapuche 
donors.22 This result differs to that of the current 
study, in which HLA-B8 alleles were roughly similar 
in both the patients and the controls. On the other 
hand, there was no positive association of HLA-A2 
alleles with ESRD in the current study; this is similar 
to the findings reported among the Zulian population 
in Venezuela, in which HLA-A2 alleles were also not 
associated with ESRD.6 
The most numerous HLA-B allele in patients was 
HLA-B5. This allele was articulated in the HESRF 
patients at a higher frequency in comparison to the 
controls (0.26 versus 0.18). This result is different from 
that reported among the Zulian population in Venezuela, 
in which HLA-B5 was less frequent in both ESRF patients 
and controls (3.9% and 2.4%, respectively).6
In the current study, a comparison of the 
frequency of HLA-CW alleles showed considerably 
higher frequencies of HLA-CW3 among the controls 
than the patients (P = 0.006), indicating the protective 
function of HLA-CW3. This result is different from 
that reported in thyrotoxicosis patients, in whom HLA-
CW3 was found to be significantly increased in patients 
with endocrine ophthalmopathy (EOP) compared to 
thyrotoxic patients without EOP.23 However, as yet, there 
have been no reported findings regarding the protective 
function of HLA-CW3 alleles in renal diseases. 
A comparison of the frequency of DRB1 alleles in 
the patients and controls showed higher frequencies 
of DRB1-8 in the control group than the patient group 
(P = 0.05), indicating the protective function of DRB1-
8. This result is different to that reported among 
Hispanic renal recipient patients, in which DRB1-
8 was found to be significantly increased in patients 
with renal failure compared with healthy donors 
(15% versus 0%).17
The results of this study demonstrate that 
HLA-A2, A9, B5, CW6, CW7, DRB1-4 and DRB1-13 
have very high frequencies among the HLA alleles in 
both patients and controls in the studied population. 
This result matches those of studies performed 
on the frequency of HLAs in Iraqi, Emirati and 
Lebanese populations.24–26 In addition, comparing 
the antigen frequencies in the current study to those 
from kidney recipients and donors of other ethnic 
groups (i.e. African-Americans, Caucasians, Asians 
and Hispanics) included in the UNOS renal registry 
data on HLA-A, B and DR loci showed that, while the 
population in the current study differed from the other 
groups in certain respects, there was a similarity with 
Hispanics and Caucasians in the highest frequencies 
of HLA alleles.17
The diversity of the findings of different 
researchers may be due to the considerable irregularity 
in the frequency of HLA alleles present in different 
populations or ethnic groups. A further cause may be 
the unequal relationship between these HLA alleles 
and other nearby genes involved in accommodating 
the immune response. An example of this is reported 
by Ranganath et al.; they stated that polymorphisms 
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in genes encoding certain cytokines, including 
interleukin (IL)-6, IL-4 and tumour necrosis factor, 
may be affected in the progression to ESRD.27 
This study had the limitation of being under-
powered as only 50 patients were studied. However, 
it has laid the groundwork for future case-control 
studies in Yemen with larger sample sizes of cases and 
controls. These future studies should aim to confirm the 
connection between class I and II HLAs and cases of 
HESRF as compared with healthy controls.
Conclusion
This study found a high association between 
HLA-A9(24) and HESRF and a highly significant 
protective function for the HLA-CW3 and DRB1-8 
genes against HESRF development. At the same time, 
the findings showed no significant role for other HLA 
molecules in the predisposition to developing ESRD 
among Yemeni patients. Although the HLA-B14 gene 
was found only in the patients and not in the control 
group, this difference was not statistically significant 
enough to conclude that the B14 gene is involved in a 
genetic predisposition to ESRD development. Certain 
HLA genes, such as HLA-A2, B5, CW6 and DRB1-
3, DRB1-4 and DRB1-13, were found to have a high 
frequency in both the patients and the controls.
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